Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Alkermes plc.

Get SEC filing alerts via email and in your feed for Alkermes plc.

ALKS

Alkermes plc.

About Alkermes plc.

Alkermes plc is a global biopharmaceutical company specializing in neuroscience-focused medicines. It develops, manufactures, and commercializes proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, primarily in the U.S. Alkermes also licenses its proprietary technologies, including extended-release injectable and NanoCrystal platforms, to partners worldwide. Its business model combines product sales, royalties, and manufacturing services, targeting patients with serious neurological and psychiatric conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Alkermes plc.

1
1
Alkermes plc. Alkermes Reports $66.5 Million Net Loss Amid Increased Operating Expenses and Avadel Acquisition

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Alkermes plc. Alkermes Reports $241.7 Million Net Income for Fiscal Year 2025, Completes Acquisition of Avadel Pharmaceuticals

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Alkermes plc. Alkermes Reports Q3 2025 Financial Results with $82.8M Net Income and Proposed Acquisition of Avadel Pharmaceuticals

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Alkermes plc. Alkermes Reports Q2 2025 Net Income of $87.1 Million, Revenue Decline Due to Lower Manufacturing and Royalty Income

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Alkermes plc. Alkermes Reports Q1 2025 Financial Results with $306.5M Revenue and $22.5M Net Income

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Alkermes plc. Alkermes Reports $372.1M Net Income for 2024, Down from $519.2M in 2023

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Alkermes plc. Alkermes Reports 18% Increase in Product Sales, Net Income Growth in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments